ArticleOncology letters2025

Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report.

Yihong Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.